Biofrontera Inc (NAS:BFRI)

Q1 2026 Biofrontera Inc Earnings Call Transcript

May 14, 2026 / 03:00 PM GMT

Release Date Price: $0.9886 (+3.00%)

Transcript 10-Q8-K

Key Points

Positve

Biofrontera Inc (BFRI) reported a 17% increase in product revenues, reaching $10.1 million in Q1 2026 compared to $8.6 million in Q1 2025.
The company's gross margin expanded significantly to approximately 80%, up from 62% in the prior year quarter.
Biofrontera Inc (BFRI) achieved near-zero cash use in operations, a dramatic improvement from $4.1 million used in Q1 2025.
The company announced positive Phase 3 clinical trial results for actinic keratosis on the extremities, neck, and trunk, supporting a supplemental NDA filing.
Biofrontera Inc (BFRI) regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing.

Negative

Operating expenses increased to $14.4 million in Q1 2026 from $13.1 million in Q1 2025, driven by higher selling, general, and administrative expenses.
The company reported a net loss of $4.8 million or $0.41 per share, compared to a net loss of $4.2 million or $0.47 per share in the prior year quarter.
Biofrontera Inc (BFRI) faces ongoing legal expenses related to patent-related claims, impacting general and administrative costs.
The company included a going concern qualification in its statements, indicating concerns about its ability to continue operations without additional capital.
There is uncertainty regarding the FDA's requirements for the acne vulgaris program, which may impact the timeline for Phase 3 trials.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

BFRI.OQ - Biofrontera Inc
Q1 2026 Biofrontera Inc Earnings Call
May 14, 2026 / 03:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to Biofrontiera Inc. First Quarter 2026 Financial Results and Business Update Conference Call.

All participant line will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key, followed by zero. After today's presentation, there will be an opportunity to ask question. To ask a question, you may press then 1 on a touchtone phone. To withdraw your question, please press then 2. Please note this event is being recorded.

I would like to turn the conference over to Ben Shamsian, Investor Relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.